Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding.

Area of Science:

• Pharmacology
• Pain Management
• Neuroscience

Background:

• Chronic pain affects a large population and is often debilitating.
• Palmitoylethanolamide (PEA) is a naturally occurring compound with analgesic and anti-inflammatory properties.
• PEA interacts with the endocannabinoid system to modulate pain and immune responses.

Purpose of the Study:

• To evaluate the efficacy of Palmitoylethanolamide (PEA) in pain management.
• To assess PEA's effectiveness across different pain types: nociceptive, neuropathic, and nociplastic.
• To determine the impact of PEA on quality of life in patients with chronic pain.

Main Methods:

• A systematic meta-analysis of randomized clinical trials was performed.
• Searches were conducted across PubMed, Embase, Scopus, and Cochrane Library databases.
• Data from 18 studies involving 1196 patients were analyzed using standard mean difference (SMD).

Main Results:

• PEA significantly reduced pain at 6, 8, and 24-26 weeks (SMD -0.9 to -1.16).
• Quality of life, including pain-related aspects, significantly improved with PEA treatment (SMD -0.61).
• PEA demonstrated effectiveness for nociceptive (SMD -0.74), neuropathic (SMD -0.97), and nociplastic (SMD -0.59) pain.

Conclusions:

• Palmitoylethanolamide (PEA) effectively alleviates pain and enhances quality of life.
• Significant benefits of PEA were observed within 4-6 weeks of treatment initiation.
• PEA presents a promising, safer alternative to chronic opioid analgesics, potentially mitigating risks of abuse and dependency.